Press Releases, News, and Events
ChromaCode making an impact

PRESS RELEASES, NEWS, AND EVENTS header image
Search

ChromaCode Announces Publication of New Study Demonstrating the Superior Performance of its HDPCR NSCLC Assay Compared to NGS with Low Sample Input

CARLSBAD, Calif., Jan. 26, 2024 /PRNewswire/ — ChromaCode, Inc., a pioneering genomics multiplexing platform company developing accessible and affordable laboratory-based solutions, today announced the publication of a study entitled “NSCLC Digital PCR Panel Returns Low Input Sample Results Where Sequencing Fails” in

Read More »

ChromaCode Announces Appointment of Mark McDonough as Chairman

CARLSBAD, Calif., Jan. 10, 2024 /PRNewswire/ — ChromaCode, Inc., a pioneering genomics multiplexing platform company developing accessible and affordable laboratory-based solutions, announces Mark McDonough as Chair of the Board, the retirement of former Chair Carol Gallagher, Pharm.D., and the appointment of Michele Park, Ph.D. to

Read More »

ChromaCode and Tennessee Oncology Sign Early Access Agreement to Collaborate on Improving Availability of Non-Small Cell Lung Cancer Biomarker Testing

CARLSBAD, Calif., Jan. 8, 2024 /PRNewswire/ — ChromaCode, Inc., a pioneering genomics multiplexing platform company developing accessible and affordable laboratory-based solutions, today announced the signing of an early access agreement with Tennessee Oncology, a nationally recognized oncology practice with 35 clinical sites

Read More »

ChromaCode Announces Publication Highlighting Advancements in HDPCR NSCLC Assay Performance, Demonstrating Advantages Over Next Generation Sequencing in Enabling Timely Results, and as a Vital ‘Rescue’ Solution when NGS is not Viable

CARLSBAD, Calif., Nov. 14, 2023 /PRNewswire/ — ChromaCode, Inc., a pioneering genomics multiplexing platform company developing accessible and affordable laboratory-based solutions, today announced the publication of a study demonstrating the performance of its HDPCR technology-based assay for non-small cell lung cancer (NSCLC). The

Read More »

ChromaCode and Protean BioDiagnostics Establish Strategic Partnership to Introduce a HDPCR-based NSCLC Assay in the U.S.

CARLSBAD, Calif., Aug. 10, 2023 /PRNewswire/ — ChromaCode, Inc., a genomics multiplexing platform company developing accessible and affordable solutions for laboratories, patients, and physicians, today announced a strategic partnership with Protean BioDiagnostics Inc., a CAP/CLIA-accredited, high-complexity laboratory specializing in developing

Read More »